A team of the Institute of Neurosciences of the University of Barcelona has participated in the design of the first light-activated drug –the JF-NP-26, for the treatment of pain, according to a research with animal models published in the journal eLife.
The new study is conducted by the teams led by Professor Francisco Ciruela, from the Faculty of Medicine and Health Sciences of the University of Barcelona, the Institute of Neurosciences of the UB and the Bellvitge Biomedical Research Institute (IDIBELL), and Amadeu Llebaria, from the MCS group of the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC).
Optopharmacology: light-operated drugs
In general, common pharmacology has important limitations –slow and inexact distribution of the drug, lack of spatiotemporal traits in the organism, difficulties in the dose adjustments, etc.– which can limit the therapeutic action of any drug. In this context, optopharmacology is an emerging discipline in pharmacology, based on the use of light to control drug activity. Therefore, using light on a photosensitive drug, the pharmacological process can be controlled with spatial and temporal precision.
The new study published on the journal eLife has come up with the design of a “photo-drug” (JF-NP-26) with powerful therapeutic applications to treat pain, a molecule that can be specifically activated at any wished moment (that is, with a high spatiotemporal resolution) with light.
“In the clinical field, there is not any precedent of the uses of optopharmacology to improve pain treatment or any disease associated with the nervous system. This is the first light-activated drug designed for the treatment of pain in vivo with animal models”, says Professor Francisco Ciruela.
Designing a toxic effect-free photosensitive compound
In this new optopharmacology proposal, a drug with a known action mechanism (for example an analgesic) is chemically modified to make it photosensitive and inactive. This drug is activated when receiving light –using an optical fiber- of a suitable wave length and with an exact precision on the target tissue (brain, skin, articulations, etc.).
The drug JF-NP-26 is also called photocaged, a chemically and inactive covered molecule which is activated with light. Compared to other photosensitive compounds, JF-NP-26 is a molecule that has no pharmacological effect on an animal until the target tissue received light from a visible spectrum (405 nm wave length). Moreover, JF-NP-26 does not show toxic or unwanted effects even if the dose is high –in short-length studies on animals.
The drug’s lightening includes a treatment on the molecule that releases the active molecule (raseglurant) that blocks the metabotropic glutamate type 5 (mGlu5) receptor, found in lots of neuronal functions such as the spread of neuronal pain. Blocking this receptor allows preventing the pain from spreading into the brain. This can be produced both due the outlying neurons and the central nervous system (brain) and create, in both cases, an analgesic effect as a result.
An analgesic effect which was not quite described so far
“The molecule created by the action of the light, the raseglurant, does not belong to any group of drugs from the classic anti-pain list of drugs: non-steroidal anti-inflammatory drugs or NSAID (paracetamol, ibuprofen, etc.) and opioids (morphine, phentanyl). Consequently, this study describes an analgesic mechanism which has not been explored enough so far” says Ciruela.
“Actually, -adds Ciruela-, the raseglurant was examined in clinical trials as an analgesic to treat migraine but it was ruled out due its hepatoxicity. This new optopharmacology of the raseglurant can stop adverse effects in the liver and opens a new path to start using it as an analgesic”.
Searching for new drugs using optopharmacology
Optopharmacology is shaping a new horizon in the findings of new drugs and administration and control methods for pharmacological action. This discipline can help widening the therapeutic range to treat pain and notably reduce the unwanted effects of lots of drugs (for example the high risk of addiction in morphine, the NSAID low analgesic efficacy in severe and chronic pain, etc.).
“If we compare natural biological molecules that act in living beings with drugs, we can see that the former can work with great precision, acting in centralized areas and with regulated doses, with defined lengths. However, the drugs we have, act in all areas and without a strict control. The use of light-controlled molecules tries to complete these spaces to get more precise drugs that can act like biological molecules” says Llebaria. The team of the Group MCS (Medicinal Chemistry & Synthesis) of IQAC is now participating in several projects on photo-pharmacology, working on the design and synthesis of several light-activated molecules. “This approach is more complex than the one on a conventional drug since, apart from the therapeutic features, the molecule’s photochemical and photophysical responses have to be prioritized” says Llebaria.
The research team of the UB and IDIBELL is working on research lines in optopharmacology to respond to lots problems related to conventional pharmacology. “At this moment we are examining other molecules with different action mechanisms but also based on G protein-coupled membrane receptors, the biggest therapeutic target at the moment. Therefore, we have drugs under study for the treatment of Parkinson’s disease or psoriasis. We are also exploring the optopharmacological use of light with different wave lengths (green, yellow and red) which are even less toxic. Regarding the future, we cannot rule out some symptomatology to be lowered with optical fibers in the brain, just like electrodes are put in the deep brain stimulation with Parkinson’s disease” concludes Ciruela.
Learn more: First photoactive drug for pain treatments
[osd_subscribe categories=’light-activated-nanotherapy’ placeholder=’Email Address’ button_text=’Subscribe Now for any new posts on the topic “LIGHT-ACTIVATED NANOTHERAPY’]
The Latest on: Light-activated drug
- Global Light Activated Therapies Market 2021-2030: Over 635 Patents have been Filed/Granted in Past 3 Years
The 'Global Light Activated Therapies Market: Distribution by Target Indications, Key Players and Geographies: Industry Trends and Global Forecasts, 2021-2030' report has been added to ...
- Banned driver went at twice speed limit and jumped red light before being caught with cannabis
A banned motorist caught driving double the speed limit while in possession of cannabis has narrowly avoided jail. Lewis Thompson, of Camellia Crescent, Norton, Stockton, appeared at Teesside Crown ...
- Can a Digital Reality Be Jacked Directly Into Your Brain?
The idea of a synthetic experience uploaded to the mind has been a sci-fi fantasy forever. New brain-computer interfaces are making it nonfiction—very slowly.
- US approves first drug for most common cause of dwarfism after children given £240,000-a-year daily injection grew half an inch in a year — but it won't be rolled out on NHS ...
A daily injection which can give children with a common form a dwarfism an extra half inch of height in a year has been approved in the US but the UK won't be appraising the drug until 2023.
- Global Light Activated Therapies Market 2021-2030: Focus on Photodynamic Therapies, Photoimmunotherapies and Photothermal Therapies - ResearchAndMarke
The "Global Light Activated Therapies Market: Distribution by Target Indications, Key Players and Geographies: Industry Trends and Global Forecasts, 2021-2030" report has been added to ...
via Google News and Bing News